source
- Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionThe wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.BioPharma Dive · 2mo ago↗ source
- A year after Vertex’s big launch, pain drug research faces a pivotal momentJournavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?BioPharma Dive · 2mo ago↗ source
- GSK cuts deal with Sino to broaden reach of hepatitis B drugThe marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.